Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MICRO-VAP
NCT07463339Phase 2Not yet recruiting
- Sponsor
- University of Calgary
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Inhalation Devices
01
Overview
Phase 2, randomised, double-blind trial of tobramycin, aztreonam and vancomycin in ventilator-associated pneumonia (VAP) (2 arms), sponsored by University of Calgary. Primary endpoints: Adherence to protocol at 36 hours and Treatment-emergent adverse events (TEAE) at 7 days. Planned start May 2026; status: not yet recruiting.
02
Drugs
tobramycinaztreonamvancomycin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07463339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463339.